TABLE 1.

Potential pharmacological targets and inhibitors targeting lipid uptake.

Drug target	Notable inhibitors	Inhibitor description	IC50	Development status	Related diseases	Chemical structure	References
FATP2	Lipofermata	—	4.84 μM	Preclinical Stage	Melanoma		Zhang et al. (2018)
CD36	ABT-510	TSP-1 mimetic drug	—	Phase 2	Melanoma; Renal cell carcinoma, Lymphoma; Glioblastoma; Brain Tumor		Campbell et al. (2010), Markovic et al. (2007), Nabors et al. (2010)
MAGL	ABX-1431	An first-in-class irreversible inhibitor	8 nM	Phase 2	Neurological disorders		Cisar et al. (2018)
MAGL	MJN110	Irreversible	9.1 nM	Preclinical Stage	Diabetes; Neuropathy		Wilkerson et al. (2016)
MAGL	JNJ-42226314	Highly selective; Non-covalent; Reversible	1.13 nM (Hela cells)	Preclinical Stage	Neuropathic and inflammatory pain		Wyatt et al. (2020)
MAGL	JZL184	The first selective MAGL inhibitor	8 nM	Preclinical Stage	T2D; Glioblastoma		Taib et al. (2019), Walenna et al. (2020)
NPC1L1	Ezetimibe	a selective inhibitor; Oral	—	FDA approved	Primary hyperlipidemia; Familial cholesterolemia		Long et al. (2021), Rocha et al. (2022)

The chemical information of small molecules is collected from Pubchem database (https://pubchem.ncbi.nlm.nih.gov), and 2D structures in the above diagram were drawn by Chemdraw software. IC50, half maximal inhibitory concentration.